LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 21

Search options

  1. Article ; Online: The utility of imputation for molecular mismatch analysis in solid organ transplantation.

    Krummey, Scott M / Cliff Sullivan, H

    Human immunology

    2022  Volume 83, Issue 3, Page(s) 241–247

    Abstract: HLA genotyping has undergone a rapid progression in resolution since the development of DNA-based typing methods. Despite the advent of high-resolution next-generation sequencing, the bulk of solid organ genotyping is performed at intermediate resolution, ...

    Abstract HLA genotyping has undergone a rapid progression in resolution since the development of DNA-based typing methods. Despite the advent of high-resolution next-generation sequencing, the bulk of solid organ genotyping is performed at intermediate resolution, which provides multiple possible two-field results for each classical HLA loci. As a result, several methodologies have been developed to impute the most likely allele-level (two-field) HLA genotype for the purposes of donor-recipient compatibility analysis. The advent of molecular mismatch analysis, however, has placed a new emphasis on the accuracy of imputation. While seminal molecular mismatch studies have relied on the imputation of intermediate resolution genotyping, several recent studies have performed analysis showing that imputation generates inaccuracies in epitope identification. While the clinical impact of these errors is not clear, it is important that these concerns do not preclude future progress in understanding the utility of molecular mismatch analysis in transplantation. In the future, advances in genotyping methods will result in routine two-field resolution that will abrogate these concerns. In the meantime, however, studies are needed in order to address the role of molecular mismatch in diverse patient populations and to carefully address the potential of molecular mismatch analysis in the context of imputation.
    MeSH term(s) Alleles ; Genotype ; HLA Antigens/genetics ; Histocompatibility Testing/methods ; Humans ; Organ Transplantation ; Tissue Donors
    Chemical Substances HLA Antigens
    Language English
    Publishing date 2022-02-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 801524-7
    ISSN 1879-1166 ; 0198-8859
    ISSN (online) 1879-1166
    ISSN 0198-8859
    DOI 10.1016/j.humimm.2021.11.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A Primer on Chimerism Analysis: A Straightforward, Thorough Review.

    Morris, Anna B / Bray, Robert / Gebel, Howard M / Cliff Sullivan, H

    Laboratory medicine

    2022  Volume 54, Issue 4, Page(s) 352–362

    Abstract: Short tandem repeat (STR) analysis to assess chimerism is a critical aspect of routine care particularly in patients facing stem cell transplants but is also relevant in other clinical scenarios. STR analysis provides a means to assess donor and ... ...

    Abstract Short tandem repeat (STR) analysis to assess chimerism is a critical aspect of routine care particularly in patients facing stem cell transplants but is also relevant in other clinical scenarios. STR analysis provides a means to assess donor and recipient cellular origins in a patient, and, as such, can inform engraftment, rejection, and relapse status in stem cell transplant recipients. In this review of STR testing, the most commonly used method to assess chimerism, its background, procedural details, and clinical utility are discussed.
    MeSH term(s) Humans ; Hematopoietic Stem Cell Transplantation ; Chimerism ; Stem Cell Transplantation ; Tissue Donors ; Recurrence
    Language English
    Publishing date 2022-11-14
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 391758-7
    ISSN 1943-7730 ; 0007-5027
    ISSN (online) 1943-7730
    ISSN 0007-5027
    DOI 10.1093/labmed/lmac132
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The pillars of patient blood management: key to successful implementation (Article, p. 2840).

    Sullivan, H Cliff / Roback, John D

    Transfusion

    2019  Volume 59, Issue 9, Page(s) 2763–2767

    MeSH term(s) Blood Transfusion ; Hematopoietic Stem Cell Transplantation ; Humans
    Language English
    Publishing date 2019-09-04
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.15464
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.

    Sullivan, H Cliff / Roback, John D

    Transfusion medicine reviews

    2020  Volume 34, Issue 3, Page(s) 145–150

    Abstract: As the world faces the current SARS-CoV-2 pandemic, extensive efforts have been applied to identify effective therapeutic agents. Convalescent plasma collected from recovered patients has been a therapeutic modality employed for over a hundred years for ... ...

    Abstract As the world faces the current SARS-CoV-2 pandemic, extensive efforts have been applied to identify effective therapeutic agents. Convalescent plasma collected from recovered patients has been a therapeutic modality employed for over a hundred years for various infectious pathogens. Specifically, it has been used in the treatment of many viral infections with varying degrees of clinical efficacy. As we consider the use of convalescent plasma in the battle against this new strain of coronavirus, it is prudent to review what is known from past experiences. Accordingly, the aim of this review is to examine in detail studies of convalescent plasma used during previous viral outbreaks and pandemics with particular focus on hemorrhagic fevers, influenza, and other coronaviruses. The concluding sections of this review address the potential use of convalescent plasma during the present-day SARS-CoV-2 pandemic, not only insofar as its clinical benefit but also the steps required to make convalescent plasma treatments readily available for an exponentially growing patient population. By the end, the authors hope to address the extent to which convalescent plasma represents a realistic therapeutic approach, or a distraction from other potentially useful treatments.
    MeSH term(s) COVID-19 ; Coronavirus Infections/therapy ; Hemorrhagic Fever, Ebola/therapy ; Humans ; Immunization, Passive ; Immunoglobulins, Intravenous/therapeutic use ; Influenza, Human/therapy ; Pandemics ; Pneumonia, Viral/therapy ; Severe Acute Respiratory Syndrome/therapy ; Treatment Outcome ; COVID-19 Serotherapy
    Chemical Substances Immunoglobulins, Intravenous
    Keywords covid19
    Language English
    Publishing date 2020-04-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 639107-2
    ISSN 1532-9496 ; 0887-7963
    ISSN (online) 1532-9496
    ISSN 0887-7963
    DOI 10.1016/j.tmrv.2020.04.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Convalescent Plasma

    Sullivan, H. Cliff / Roback, John D.

    Transfusion Medicine Reviews

    Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic

    2020  Volume 34, Issue 3, Page(s) 145–150

    Keywords Clinical Biochemistry ; Hematology ; Biochemistry, medical ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 639107-2
    ISSN 1532-9496 ; 0887-7963
    ISSN (online) 1532-9496
    ISSN 0887-7963
    DOI 10.1016/j.tmrv.2020.04.001
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Indeterminate group A subtyping for prospective renal transplant donor.

    Achram, Robert / Zerra, Patricia E / Delvadia, Bhaveshkumar / Thompson, Louisa / Badell, I Raul / Roback, John D / Sullivan, H Cliff

    Transfusion

    2022  Volume 62, Issue 9, Page(s) 1927–1928

    MeSH term(s) Graft Survival ; Humans ; Kidney ; Kidney Transplantation ; Living Donors ; Prospective Studies ; Tissue Donors
    Language English
    Publishing date 2022-08-16
    Publishing country United States
    Document type Letter
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.17047
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: hlaR: A rapid and reproducible tool to identify eplet mismatches between transplant donors and recipients.

    Johnson, Aileen C / Zhang, Joan / Cliff Sullivan, H / Wiebe, Chris / Bray, Robert / Gebel, Howard / Larsen, Christian P

    Human immunology

    2022  Volume 83, Issue 3, Page(s) 248–255

    Abstract: Eplet mismatch load, both overall and at the single molecule level, correlates with transplant recipient outcomes. However, precise eplet assessment requires high-resolution HLA typing of both the donor and recipient. Anything less than high-resolution ... ...

    Abstract Eplet mismatch load, both overall and at the single molecule level, correlates with transplant recipient outcomes. However, precise eplet assessment requires high-resolution HLA typing of both the donor and recipient. Anything less than high-resolution typing requires imputation of HLA types. The currently available methods to identify eplet mismatch are both tedious and demanding. Therefore, we developed a software package and user-friendly web application (hlaR), that simplifies the workflow of eplet analysis, provides functions to impute high-resolution from low-resolution data and calculates both overall and single molecule eplet mismatch for single or multiple donor recipient pairs. Compared to manual assessments using currently available tools (namely, HLAMatchMaker), hlaR resulted in only minimal discrepancy in eplet mismatches (mean absolute difference of 0.56 for class I and 0.86 for class II for unique sum across loci). Additionally, output of the single molecule eplet function compared well to manual calculation, with an average single antigen count increase of 0.19. Importantly, the hlaR tool permits rapid and reproducible imputation and eplet mismatch including comparison between eplet reference tables (e.g. HLAMatchMaker version 2 or 3). Users can import data from a spreadsheet rather than relying on keystroke entry of individual donor and recipient data, thus reducing the risk of data entry errors. The resulting improved scalability of the hlaR tool is highlighted by plotting analysis time against the size of the input dataset. The new hlaR tool can provide eplet mismatch data with a streamlined workflow. With decreased effort from the end user, eplet matching and mismatch load data can be further incorporated into both research and clinical use.
    MeSH term(s) Graft Rejection ; HLA Antigens/genetics ; Histocompatibility Testing/methods ; Humans ; Kidney Transplantation ; Tissue Donors ; Transplant Recipients
    Chemical Substances HLA Antigens
    Language English
    Publishing date 2022-01-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 801524-7
    ISSN 1879-1166 ; 0198-8859
    ISSN (online) 1879-1166
    ISSN 0198-8859
    DOI 10.1016/j.humimm.2022.01.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Three patients highlighting potential pitfalls in platelet refractory testing.

    Attieh, Michel / Dent, Edward A / Happney, Logan / Roback, John D / Alter, David N / Barrette, Eileen / Then, Caroline / Sullivan, H Cliff

    Transfusion

    2023  Volume 63, Issue 4, Page(s) 888–892

    Abstract: Background: Platelet-transfusion refractory (PR) patients do not achieve expected post-transfusion platelet counts. We investigate suspected PR patients with post-transfusion platelet counts, indirect platelet antibody screens (ind-PAS), Class I HLA ... ...

    Abstract Background: Platelet-transfusion refractory (PR) patients do not achieve expected post-transfusion platelet counts. We investigate suspected PR patients with post-transfusion platelet counts, indirect platelet antibody screens (ind-PAS), Class I HLA antibody tests (HLA-Scr), and physical platelet crossmatch (PXM) studies.
    Study design and methods: The three following cases describe possible pitfalls of laboratory tests used in PR workup and management.
    Results: Case #1: Antibody testing detected antibodies to only HLA-B13, corresponding to a 4% calculated panel reactive antibodies (CPRA; 96% predicted donor compatibility). However, PXM showed the patient compatible with 11/14 (79%) donors; two of the PXM-incompatible units were ABO-incompatible. Case #2: PXM revealed compatibility with 1/14 screened donors; however, the patient did not respond to the product from the compatible donor. The patient did respond to HLA-matched product. Dilution studies provided evidence of the prozone effect, which caused negative PXM despite clinically relevant antibodies. Case #3: There was a discrepancy between the ind-PAS and HLA-Scr. Ind-PAS was negative for HLA antibodies, while HLA-Scr was positive and specificity testing corresponded to 38% CPRA. Per the package insert, the sensitivity of ind-PAS is ~85% compared to HLA-Scr.
    Discussion: These cases highlight the importance of investigating incongruent results. Cases #1 and #2 demonstrate PXM pitfalls: ABO incompatibility can result in positive PXM and false-negative PXM can occur in the setting of the prozone effect. Case #3 reveals the importance of knowing a test's sensitivity. Centers that only perform ind-PAS may fail to detect HLA antibodies.
    MeSH term(s) Humans ; Antibodies ; Blood Grouping and Crossmatching ; Blood Platelets ; Histocompatibility Testing ; HLA Antigens ; Platelet Count ; Platelet Transfusion/methods
    Chemical Substances Antibodies ; HLA Antigens
    Language English
    Publishing date 2023-02-16
    Publishing country United States
    Document type Case Reports
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.17280
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic

    Sullivan, H Cliff / Roback, John D

    Transfus Med Rev

    Abstract: As the world faces the current SARS-CoV-2 pandemic, extensive efforts have been applied to identify effective therapeutic agents. Convalescent plasma collected from recovered patients has been a therapeutic modality employed for over a hundred years for ... ...

    Abstract As the world faces the current SARS-CoV-2 pandemic, extensive efforts have been applied to identify effective therapeutic agents. Convalescent plasma collected from recovered patients has been a therapeutic modality employed for over a hundred years for various infectious pathogens. Specifically, it has been used in the treatment of many viral infections with varying degrees of clinical efficacy. As we consider the use of convalescent plasma in the battle against this new strain of coronavirus, it is prudent to review what is known from past experiences. Accordingly, the aim of this review is to examine in detail studies of convalescent plasma used during previous viral outbreaks and pandemics with particular focus on hemorrhagic fevers, influenza, and other coronaviruses. The concluding sections of this review address the potential use of convalescent plasma during the present-day SARS-CoV-2 pandemic, not only insofar as its clinical benefit but also the steps required to make convalescent plasma treatments readily available for an exponentially growing patient population. By the end, the authors hope to address the extent to which convalescent plasma represents a realistic therapeutic approach, or a distraction from other potentially useful treatments.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #108960
    Database COVID19

    Kategorien

  10. Article ; Online: Implementing virtual crossmatch based diagnostic management teams in human leukocyte antigen laboratories and transplant programs.

    Wade, Jenna / Roback, John D / Krummey, Scott M / Gebel, Howard M / Bray, Robert A / Sullivan, H Cliff

    Transplant immunology

    2022  Volume 73, Page(s) 101629

    Abstract: Histocompatibility testing has continuously evolved since its inception. One such advancement is the implementation of the virtual crossmatch (VXM). Recent changes to allograft allocation schemes have resulted in increased organ sharing over greater ... ...

    Abstract Histocompatibility testing has continuously evolved since its inception. One such advancement is the implementation of the virtual crossmatch (VXM). Recent changes to allograft allocation schemes have resulted in increased organ sharing over greater distances, resulting in expanded utilization of the VXM to assess donor: recipient compatibility. In fact, the VXM has become a major arbitrator of pre-transplant compatibility assessment prior to both deceased and living donor organ allocation. This shift in pre-transplant practice is concurrent with the US healthcare systems' move towards more inclusive and coordinated team-based management approach to disease diagnosis. Diagnostic Management Teams (DMTs) exemplify this shift in patient care. Our institution seized the opportunity to build and implement a VXM DMT to improve and streamline pre-transplant assessment. This VXM DMT is compliant with US regulatory standards and provides a consultative report containing relevant pre-transplant information, test interpretation as well as recommendations for HLA additional (if any) testing. Herein we describe the development of and experience with the VXM DMT a year after its launch.
    MeSH term(s) Blood Grouping and Crossmatching ; HLA Antigens ; Histocompatibility Antigens Class I ; Histocompatibility Antigens Class II ; Histocompatibility Testing/methods ; Humans ; Isoantibodies ; Laboratories ; Living Donors
    Chemical Substances HLA Antigens ; Histocompatibility Antigens Class I ; Histocompatibility Antigens Class II ; Isoantibodies
    Language English
    Publishing date 2022-05-21
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1160846-8
    ISSN 1878-5492 ; 0966-3274
    ISSN (online) 1878-5492
    ISSN 0966-3274
    DOI 10.1016/j.trim.2022.101629
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top